Patents by Inventor Jonathan HEAL

Jonathan HEAL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nutraceutical compositions
    Patent number: 11986457
    Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: May 21, 2024
    Assignee: SPECNOVA LLC
    Inventors: Sebastian Balcombe, William Hamilton, Jonathan Heal, Joseph Sheridan
  • Nutraceutical compositions
    Patent number: 11925615
    Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: March 12, 2024
    Assignee: SPECNOVA LLC
    Inventors: Sebastian Balcombe, William Hamilton, Jonathan Heal, Joseph Sheridan
  • NOVEL NUTRACEUTICAL COMPOSITIONS
    Publication number: 20220296562
    Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.
    Type: Application
    Filed: March 16, 2022
    Publication date: September 22, 2022
    Applicant: SpecNova LLC
    Inventors: Sebastian BALCOMBE, William HAMILTON, Jonathan HEAL, Joseph SHERIDAN
  • NOVEL PHARMACEUTICAL COMPOSITIONS
    Publication number: 20220296537
    Abstract: The invention relates to pharmaceutical compositions comprising dopamine transporter inhibitors and to their use in the prophylaxis or treatment of disease states or conditions mediated by the dopamine transporter.
    Type: Application
    Filed: March 16, 2022
    Publication date: September 22, 2022
    Applicant: SpecNova LLC
    Inventors: Sebastian BALCOMBE, William HAMILTON, Jonathan HEAL, Joseph SHERIDAN
  • CD200 mutants and its uses
    Patent number: 11203628
    Abstract: The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein encoding portion via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: December 21, 2021
    Assignee: Ducentis Biotherapeutics Ltd.
    Inventors: Philip Huxley, Joseph Sheridan, Jonathan Heal
  • CD200 MUTANTS AND ITS USES
    Publication number: 20190367580
    Abstract: The invention relates generally to mutant CD200 proteins which bind with greater affinity to the CD200 receptor than wild-type CD200, in particular the invention relates to a mutated CD200 protein comprising a mutation at amino acid residue position 130 and/or 131. This invention also relates to a fusion protein comprising the protein as defined herein fused to a non-CD200 protein encoding portion via an optional linker portion, a pharmaceutical composition comprising the protein as defined herein and uses thereof.
    Type: Application
    Filed: May 10, 2017
    Publication date: December 5, 2019
    Inventors: Philip HUXLEY, Joseph SHERIDAN, Jonathan HEAL